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EmphysemaMethods: Inspiratory and expiratory CTs were performed in 1140 male smokers without or with
mild COPD to quantify emphysema, airway wall thickness and air trapping. Spirometry, resid-
ual volume to total lung capacity (RV/TLC) and diffusion capacity (Kco) were measured. Domi-
nant phenotype (emphysema, airway wall thickening or air trapping dominant) was defined as
one of the respective CT measure in the upper quartile, with the other measures not in the
upper quartile.
Results: 573 subjects had any of the three CT measures in the upper quartile. Of these, 367
(64%) were in a single dominant group and 206 (36%) were in a mixed group. Airway wall thick-
ening dominance was associated with younger age (p < 0.001), higher body mass index
(p < 0.001), more wheezing (p < 0.05) and lower FEV1 %predicted (p < 0.001). Emphysema
dominant subjects had lower FEV1/FVC (p < 0.05) and Kco %predicted (p < 0.05). There was
no significant difference in respiratory related hospitalizations (p Z 0.09).
Conclusion: CT measures can discriminate three different CT dominant groups of disease in
male smokers without or with mild COPD.
Trial registration number: ISRCTN63545820, registered at www.trialregister.nl.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is the only
chronic disease with increasing mortality rates and has a
high morbidity worldwide [1]. COPD is mainly caused by
inhalation of irritants found in tobacco smoke and is diag-
nosed when COPD is present, i.e. when the FEV1/FVC is
below a predefined threshold [2,3].
Lung abnormalities associated with COPD may represent
a continuum of a single disorder or may consist of multiple
largely independent types. Small airways are believed to
represent the principal site of obstruction in most patients
with obstructive pulmonary disease [3,4]. Classical belief is
that centrilobular emphysema starts with disappearance of
small airways followed by emphysematous destruction. In a
final stage only a few thickened large airways persist [3].
However, this sequence in the pathophysiology of cen-
trilobular emphysema does not exclude that intrinsic small
and large airway disease can independently lead to
obstructive pulmonary disease without emphysematous
destruction in other large groups of smokers. Nakano et al.
showed that, in patients with more advanced stages of
COPD, those with predominantly thickened airway walls
and with predominantly emphysema (measured as low
attenuation areas) could be identified on computed to-
mography (CT) scans [5,6]. However, there is little evi-
dence if this is also the case in smokers without COPD or
subjects only with mild COPD. Further evidence for specific
independent morphologic phenotypes comes from the
observation that ‘emphysema-dominance’ and ‘airway-
dominance’ runs in families [7].
The search for dominant COPD phenotypes is highly
relevant as large randomized controlled drug trials failed to
demonstrate significant treatment effects on lung function
decline [8,9]. It is however anticipated that within
different COPD phenotypes specific (pharmacological)
therapies might be effective [10]. Specific phenotypes
might also be associated with different prognosis, co-
morbidities and genotypes [11]. CT imaging may be one of
the tools used to phenotype COPD based on the presence of
emphysema, airway wall thickening and air trapping.We hypothesized that it would be possible to discrimi-
nate emphysematous, large airway wall thickening and
small airways disease dominant phenotypes in smokers
without or with mild COPD. We therefore studied differ-
ences in clinical symptoms, pulmonary function and respi-
ratory related hospitalization in three predominant
phenotypes (emphysema, airway wall thickening or air
trapping) based on CT parameters.
Methods
Subject selection
This study was conducted as a sub-study of the Dutch and
Belgium Lung Cancer Screening Trial (NELSON trial e
ISRCTN63545820, registered at www.trialregister.nl) and
only subjects from the University Medical Center Utrecht
were included [12]. Details of the selection procedure have
previously been described [13]. In short, subjects were
50e75 years old, current or former heavy smokers (ceased
smoking 10 years before entering the study), with a
smoking history of at least 16.5 packyears [12]. An expira-
tory acquisition was added to the screening protocol in the
University Medical Center Utrecht, The Netherlands. Of the
1162 subjects 22 were excluded because of missing smoking
history data or CT segmentation errors, resulting in 1140
subjects included. Respiratory related hospitalization rates
were retrospectively ascertained through linkage with the
National Registry of Hospital Discharge Diagnoses for the
period 1995e2007. The lung cancer screening study was
approved by the Ministry of Health of The Netherlands and
the institutional ethical review board of the University
Medical Center Utrecht, The Netherlands (IRB approval
number 03/040). Written informed consent was obtained in
all screening trial subjects.
Clinical measurements
Detailed smoking characteristics and symptoms were ob-
tained through a questionnaire. We asked for presence of
138 F.A.A. Mohamed Hoesein et al.the following symptoms: cough, mucus production, dyspnea
and wheezing, present for at least three months per year.
We retrieved causes of hospital admission through the Na-
tional Registry of Hospital Discharge Diagnoses. We
included events that occurred between January 1995 and
January 2008. All events were classified using the 9th
revision of the International Classification of Diseases, and
codes 460-519 were included [14,15].
Pulmonary function testing
Information of the pulmonary function tests, including
spirometry and body plethysmography, has been reported
elsewhere [16]. Data was obtained according to European
Respiratory Society/American Thoracic Society (ERS/ATS)
guidelines and was performed with ZAN equipment (ZAN
Messgera¨te GmbH, Germany) [17,18]. Measurements
included forced expiratory volume in one second (FEV1),
forced vital capacity (FVC), mid expiratory flow at 50% of
FVC (MEF50), residual volume (RV), total lung capacity (TLC)
and the transfer coefficient for carbon monoxide (Kco) as
measure of lung diffusion capacity. The FEV1/FVC and re-
sidual volume to total lung capacity (RV/TLC) were
expressed as percentage. The Kco was used as a measure of
lung diffusion capacity.
CT scanning
The CT protocol has been described in detail before
[13,19]. All CTs were performed without intravenous
contrast injection, and obtained with 16  0.75 mm colli-
mation on the same scanner (Brilliance 16P, Philips Medical
Systems, USA). Volumetric inspiratory and end-expiratory
CT scans were obtained after standardized breathing in-
structions in all subjects. The expiratory CT scan was ob-
tained directly after the inspiratory one during the same
session. Axial images were reconstructed from lung bases to
lung apices at a slice thickness of 1.0 mm at 0.7 mm
increment, using a smoothed reconstruction filter (B-filter,
Philips).
Quantitative CT assessment of the lung parenchyma
All quantifications were performed with CIRRUS Lung 12.03
(http://cirrus.diagnijmegen.nl, Diagnostic Image Analysis
Group Nijmegen, The Netherlands; Fraunhofer MEVIS, Bre-
men, Germany). As previously described, the lungs were
automatically segmented from the chest wall, airways and
mediastinum using dedicated software [20,21]. We defined
CT emphysema as the percentage of voxels below Houns-
field Unit (HU) 950 and CT air-trapping as the expiratory
mean lung density in HU divided by the inspiratory mean
lung density expressed as percentage [13,22,23].
Quantitative CT assessment of large airways
The airway lumen was automatically segmented. Airway
cross-sections are defined perpendicular to the local airway
direction at a spacing of 1 mm across all airway centerlines.
Inner and outer airway wall borders are segmented for each
of these cross-sections based on an intensity-integrationbased analysis of 72 rays pointing radially from the cen-
terpoint outwards [24]. Cross-sections obtained from the
trachea, main bronchi, branching regions as well as cross-
sections where the airway wall segmentation failed were
automatically discarded from further analysis. The airway
lumen was automatically segmented, airways up until the
11th generation were included for analysis. The square root
of wall area for a theoretical airway with 10 mm lumen
perimeter (ZPi10) was calculated and was used as mea-
surement of airway wall thickening (ZAWT) [7,24,25]. For
each CT scan a random selection of cross-sections of the
detected airway walls borders was visually inspected to
assess if the automatic wall segmentation was correct.
Definition of dominant CT groups
Dominant emphysema, AWT dominant and dominant air
trapping were defined as the respective CT measure in the
upper quartile, with the other measures outside the upper
quartile.
Data analysis
As no established thresholds exist, we arbitrarily used the
upper quartile (values above the 75th percentile) for
presence of significant CT emphysema, CT AWT and CT air
trapping. Since CT density has been reported to be
dependent on smoking status, the 75th percentile for
emphysema was calculated for former and current smokers
separately. No significant disease was defined as all mea-
sures were outside the upper quartile. Mixed disease was
defined as multiple CT measures were in the upper quar-
tile. Descriptive statistics are presented as mean (standard
deviation (SD)) for normally distributed variables, and as
median and inter-quartile range (IQR) for non-normally
distributed variables. Differences between groups are
illustrated using box plots. Statistical significance was
tested only between the 3 dominant groups using analysis
of variance and post-hoc Bonferroni tests for normally
distributed variables, and using KruskaleWallis and post-
hoc ManneWhitney-U tests for non-normally distributed
values. P < 0.05 was considered statistically significant. All




The 1140 included males were slightly over 60 years old and
smoked on average 41 packyears. Approximately 50% were
current smokers. In this population 61.7% did not reach the
Global initiative on Obstructive Lung Disease (GOLD)
criteria for COPD. The majority of COPD subjects (86%)
were in GOLD stage 1, 14% had GOLD stage 2 or 3. About a
quarter of the population reported the presence of all four
recorded respiratory symptoms. In total 62 (5.2%) subjects
were hospitalized at least once for a respiratory disease
between 1995 and 2007. More detailed characteristics are
presented in Table 1.
Table 1 Characteristics of the included 1140 male
subjects.
Characteristic N Value
Age (yrs) mean  SD 1140 62.5  5.2
Smoking (packyears) mean  SD 1140 41.0  18.0
Current smoker (Number, %) 1140 609, 53.4%
BMI (kg/m2) 1140 27.1  3.6
GOLD stage 0 (Number, %) 703, 61.7%
1 (Number, %) 277, 24.3%
2e3(Number, %) 160, 14.0%
FEV1 (%pred) mean  SD 1140 94.8  17.6
FEV1/FVC (%) mean  SD 1140 70.9  9.3
MEF50 (%pred) mean  SD 1140 68.8  29.3
RV/TLC (%) mean  SD 418 35.9  8.4
Kco (%pred) mean  SD 420 87.7  17.4
Cough (Number, %) 1037 327, 28.7%
Mucus (Number, %) 1120 300, 26.3%
Dyspnea (Number, %) 1035 288, 25.3%




CT emphysema % voxels
< 950HU median, IQR
1140 0.75, 0.40-1.46
CT airway wall thickness at
lumen perimeter 10-mm
mean  SD
1120 2.4  0.51




1140 83.8  6.2
SD Z standard deviation, BMI Z body mass index,
GOLD Z Global Initiative on Obstructive Lung Disease,
FEV1 Z forced expiratory volume in one second, FVCZ forced
vital capacity, MEF Z mid expiratory flow, RV Z residual vol-
ume, TLC Z total lung capacity, Kco Z transfer coefficient for
carbon monoxide, IQR Z inter-quartile range, CT Z computed
tomography, HU Z Hounsfield unit.
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The 75th percentile for CT emphysema was 1.23% and 1.72%
for current and former smokers, respectively. The 75th
percentile for CT air-trapping was 87.8% and the 75th
percentile for CT airway wall thickening was 2.74 mm. A
number of 547 (49%) subjects had all three CT measures
below the 75th percentile. Of the 573 subjects with any of
the three CT measure in the upper quartile, 367 (64%) were
in a single dominant group, and 206 (36%) were in a mixed
group. Of all included subjects 143 (13%) subjects were
emphysema dominant, 91 (8%) air trapping dominant and
133 (12%) AWT dominant. Fig. 1 illustrates CT images of
subjects with GOLD stage 2 in each of the dominant groups.
Differences between dominant groups
Fig. 2 and Table 2 illustrate and present the differences
between the dominance groups based on imaging parame-
ters for clinical, and lung function characteristics. AWT
dominant subjects were on average significantly youngercompared to the emphysema (p Z 0.002) and air trapping
(p Z 0.048) dominant subjects. The three groups had
smoked a similar number of packyears (p Z 0.14) and
smoking status did not differ between the groups
(pZ 0.13). AWT dominant subjects had on average a higher
BMI compared to the emphysema (p < 0.001) and air
trapping dominant subjects (p < 0.001).
For lung function measures, the AWT dominant group
had a significantly worse FEV1 %predicted compared to the
emphysema (p < 0.001) and air trapping (p Z 0.001)
dominant groups. Emphysema dominant subjects had a
significantly worse FEV1/FVC% compared to the air trapping
(p < 0.001) and AWT (p Z 0.02) dominant groups. Kco %
predicted was significantly worse in the emphysema sub-
jects compared to both the air trapping (pZ 0.02) and AWT
(p < 0.001) dominant groups. The distribution of GOLD
stages between the three groups did not reach statistical
significance.
The air trapping dominant group had a significantly
higher MEF50 %predicted compared to the emphysema
(pZ 0.002) and AWT (pZ 0.02) dominant groups. The RV/
TLC% was not different between the groups (p Z 0.29).
The reported presence of cough (pZ 0.07) and dyspnea
(p Z 0.55) did not reach significance between the three
groups. Mucus production was reported more often in the
AWT dominant group compared to the air trapping domi-
nant group (p Z 0.02). Wheezing was significantly more
common in the AWT dominant group compared to the air
trapping (p Z 0.02) and emphysema (p Z 0.04) dominant
groups.
Differences between mixed morphological groups
Table 3 lists the differences between the mixed morpho-
logical groups based on imaging parameters regarding
clinical, and lung function characteristics. Overall, spiro-
metric measurements were significantly lower in the mixed
groups compared to the dominant groups, all p <0.05.
Respiratory related hospitalizations
Subjects with respiratory related hospitalizations had a
significantly lower FEV1, 89.5% (19.6) compared to 95.1%
(17.4) for those without (p < 0.001). The same was
observed for FEV1/FVC, 68.5% (11.3) versus 71.05% (9.2)
(p < 0.001). There were no significant differences in res-
piratory related hospitalizations between the emphysema,
AWT, air trapping and mixed type dominant groups
(p Z 0.09).
Discussion
In a population of current and former smoking males
without and with mild COPD we demonstrated that CT im-
aging grouped the majority of subjects into either the
upper quartile for CT emphysema, CT air trapping or CT
AWT, while fewer subjects demonstrated a mixture of CT
abnormalities in the upper quartile. Additionally we
observed significant differences in clinical characteristics
between subjects with dominancy for CT measured
emphysema, air trapping and AWT, including differences in
Figure 1 Patients with similar stage of Chronic Obstructive Pulmonary Disease but with different dominant abnormalities of
chest Computed Tomography. A: GOLD stage 2 with dominant airways disease. The low-dose inspiratory CT scan illustrates
thickened airway walls (white arrow) and absence of emphysema. B: GOLD stage 2 with dominant emphysematous disease. The
white arrows point at emphysema. The low-dose inspiratory CT scan visualizes marked emphysematous destruction and note the
thinner airway walls compared to figure A. C: GOLD stage 2 with dominant air trapping. The inspiratory low-dose CT scan note the
thinner airway walls compared to figure A and the absence of emphysema. D: The ultra low-dose expiratory CT scan shows air
trapping in the lower lobes with lower density compared to the middle lobe and lingula and bulging of the fissures. Also note the
collapse of airways.
140 F.A.A. Mohamed Hoesein et al.respiratory symptoms and lung function measures. Our data
thus provides evidence that also in smokers without or only
mild COPD CT may be used as a tool to identify different
phenotypes.
It seems that subjects with relatively lower lung function
values, i.e. more progressive disease, more often show a
mixed dominant pattern. These results confirm both the
notion that dominant morphologic groups indeed exists as
was proposed by Nakano et al., and that end-stage cen-
trilobular emphysema is characterized by extensive oblit-
eration of small airways and thickened large airway walls
[3,6]. However, to firmly establish phenotypes within
COPD, further research is needed, especially combining
more subjects’ characteristics and the full range of COPD
severity.
There are suggestions that there could be an association
between emphysema and airway wall thickening. Johha-
nessen et al. showed that the effect of airway wall thick-
ening on mortality was only present in subjects with severe
emphysema and not in subjects without or with moderate
emphysema. Our results show a similar trend as we showed
that the mixed morphological groups have lower spiro-
metric values.
The results can be of significance for studies investi-
gating effects of pharmacotherapy of COPD. Especially in
the mild stage of the disease, which is most interesting
from a therapeutic perspective, these CT measures may
be helpful as our data provided dominant groups insubjects without or with mild COPD. Very recently large
randomized controlled trials could not show that phar-
macological treatment was beneficial on FEV1-decline.
[8,9] These studies however did not analyze the effects
within different phenotypes of COPD. Using the CT based
types one might show effects of therapy within the
groups. Our approach can be used to appreciate COPD
more as a heterogeneous group of disorders, instead of
one disease [26].
A key point of our study is that CT phenotypes are also
already recognizable in smokers without or only mild COPD.
Although previous studies included COPD subjects with
more severe disease (GOLD 2 and higher), our findings on
the relation between CT measures and other subject
characteristics correspond favorably to previous observa-
tions. It has been shown that airway wall thickness is more
closely related to worse FEV1 %predicted, more respiratory
symptoms and higher BMI [27e30]. Furthermore, our finding
that emphysema dominant subjects show the worst
diffusion capacity is expected and confirms a previous
study [31].
We could, however, not show significant differences in
respiratory related hospitalizations between the different
CT based groups. This is explained because the included
group of subjects is relatively healthy and subsequently the
number of hospitalizations in this group is low. A recent
study including only COPD subjects showed that airway wall
thickening and emphysema were related with exacerbation
Figure 2 Box plots of different phenotypes based on CT parameters and subject demographics and results from lung function
tests (FEV1 %predicted, MEF50 %predicted, RV/TLC, RV %predicted and Kco %predicted). CT groups; normal, all measures below the
upper quartile; Q950, emphysema in the upper quartile; EI, air trapping in the upper quartile; Pi10, airway wall thickening in the
upper quartile; mixed, more than one CT measure in the upper quartile.
Discriminating dominant CT phenotypes in smokers 141frequency. However, exacerbation rate in that study was
self-reported and thus also included less severe exacerba-
tions not requiring hospitalization [32]. In another study,
lung function did relate with respiratory related hospitali-
zation and it seems that in a relatively healthy group of
subjects CT metrics do not associate with respiratory
related hospitalizations [33].
A strength of our study is that we were able to include a
large number of subjects who all underwent extensive
pulmonary function testing, and that we studied mild
stages of COPD. However, future longitudinal studies areTable 2 Characteristics of the subjects per computed tomograp







Age (yrs) 63.7  5.5 63.2  5.3
Smoking (packyears) 39.0  15.6 37.6  14.9
Current smoker (N, %) 70, 49.0% 55, 60.4%
BMI (kg/m2) 25.9  3.5 25.6  3.1
FEV1 (%pred) 97.7  14.8 97.7  16.0
FEV1/FVC (%) 68.6  7.2 72.2  7.3
MEF50 (%pred) 61.3  20.6 71.8  26.4
RV/TLC (%) 35.0  7.0 37.2  6.4
Kco (%pred) 76.6  15.7 86.7  12.8
Cough present (N, %) 33, 25.8% 26, 31.7%
Mucus present (N, %) 38, 29.5% 18, 22.8%
Dyspnea present (N, %) 35, 26.1% 18, 21.7%
Wheeze present (N, %) 19, 14.8% 12, 14.8%
Respiratory related
hospitalization (N, %)
15, 10.5% 3, 3.3%
Values in bold represents p value lower than 0.05.needed to confirm and extend our findings. Our study also
has some limitations. Firstly, although for CT emphysema
and airway wall dimensions pathological correlation
studies are available, there is no true pathological corre-
lation for the ratio between expiratory and inspiratory of
mean lung density, which we used to assess air trapping in
this study [34,35]. There is no real consensus on which cut-
off value of quantitative CT measures is the most appro-
priate and we therefore choose to use the 75th percentile.
Although this is not based on a correlation with pathology







61.5  4.8 0.02
41.7  17.0 0.138
80, 60.2% 0.13
28.1  3.5 <0.001
90.6  13.7 <0.001
71.0  7.2 <0.001
63.2  23.0 0.02
36.6  7.2 0.293


























Age (yrs) 64.5  4.8 64.0  5.5 63.6  6.5 62.8  6.0 0.394
Smoking (packyears) 45.5  18.6 45.5  21.9 43.4  16.1 44.4  19.0 0.965
Current smoker (N, %) 30, 56.6% 41, 64.0% 10, 55.6% 39, 54.9% 0.725
BMI (kg/m2) 25.9  4.3 25.0  3.9 28.4  4.6 27.9  3.7 <0.001
FEV1 (%pred) 64.2  19.6 84.4  21.3 84.1  18.9 80.3  17.7 <0.001
FEV1/FVC (%) 51.9  10.9 60.3  10.4 65.0  9.0 65.8  9.0 <0.001
MEF50 (%pred) 25.7  14.4 44.1  25.3 48.8  22.5 49.1  22.6 <0.001
RV/TLC (%) 44.9  13.4 42.6  10.1 35.8  8.7 40.1  10.5 0.367
Kco (%pred) 76.3  16.7 71.1  18.3 94.5  9.4 93.0  20.3 <0.001
Cough present (N, %) 30, 61.2% 27, 44.3% 9, 52.9% 21, 33.9% 0.034
Mucus present (N, %) 21, 45.7% 30, 50.0% 8, 53.3% 17, 27.4% 0.045
Dyspnea present (N, %) 25, 52.1% 29, 46.8% 6, 40.0% 29, 43.9% 0.798
Wheeze present (N, %) 20, 44.4% 16, 27.1% 7, 46.7% 24, 36.9% 0.250
Respiratory related
hospitalization (N, %)
3, 5.7% 4, 6.3% 1, 5.6% 2, 2.8% 0.804
Values in bold represents p value lower than 0.05.
142 F.A.A. Mohamed Hoesein et al.attractive cut-off. We choose not to correct for lung
volume since no studies yet showed this is more accurate
when compared with the gold standard for emphysema,
i.e. pathology specimen. In addition lung volume correc-
tion is deemed to play a significant role mainly in follow-up
studies [36]. Secondly, our study has a cross-sectional
design and one cannot exclude that the dominant groups
are just at various stages of a single disease. However, we
think it would be highly unlikely that subjects could start
at various distinct imaging patterns within a single disease.
Also the differences in multiple variables between the
groups suggest that these are indeed independent groups
of subjects. This would confirm the existence of emphy-
sema dominant and AWT dominant groups on CT, and we
propose to add the lung density ratio in further phenotype
research [6]. Thirdly, we used pre-bronchodilator spirom-
etry, low-dose CT protocols and obtained hospitalization
data from a validated national database of physician
recorded discharge diagnosis. Differences between groups
may have become significant if exacerbations of COPD that
did not require hospitalization would also have been
available. Fourthly, no female subjects were included.
Lastly, we concentrated only on emphysema, air trapping
and airway wall thickening and did not investigate signs of
interstitial lung disease (i.e. measures of ground glass,
bronchiectasis, etc.) which is gaining importance in
these heavy smokers [37].
In conclusion, our study provides further evidence
that even smokers with no or only mild COPD can
show specific and independent groups of disease. CT mea-
sures of emphysema, airway wall thickening and air
trapping may aid in the detection of ‘treatable’ COPD
groups (in more advanced disease), and may aid in prog-
nostication regarding pulmonary disease progression and
co-morbidities in COPD.Conflict of interest
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